CEO exercised or converted 35K ARWR derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Dec 29, 2025
- Reporting period
- Not applicable
- Filed with the SEC
- Dec 30, 2025
CEOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001423029-25-000009
Added to OQROOct 6, 2026, 4:40 PM UTC Data qualityVerified: identifiers matched exactly IssuerARROWHEAD PHARMACEUTICALS, INC. Reporting personChristopher Richard Anzalone RelationshipDirector, Officer Officer titleChief Executive Officer SecurityStock Option (right to buy Common Stock) TableDerivative (Table II) Transaction dateDec 29, 2025 Acquired / disposedDisposed (D) Footnotes from the filing
- All options were fully vested and exercisable as of January 1, 2016.
Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Gift or transfer — classified separately from trades.